Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia

Claus, 2003, Epigenetic targets in hematopoietic malignancies, Oncogene, 22, 6489, 10.1038/sj.onc.1206814 Racanicchi, 2005, Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells, EMBO J, 24, 1232, 10.1038/sj.emboj.7600593 Guidez, 1998, Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia, Blood, 91, 2634, 10.1182/blood.V91.8.2634.2634_2634_2642 Berg, 2006, Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines, Leukemia Res Cimino, 2006, Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia, Cancer Res, 66, 8903, 10.1158/0008-5472.CAN-05-2726 Tang, 2004, Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1, Leukemia, 18, 1246, 10.1038/sj.leu.2403390 Ten Cate, 2007, The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells, Leukemia, 21, 248, 10.1038/sj.leu.2404477 Gurvich, 2004, Histone deacetylase is a target of valproic acid-mediated cellular differentiation, Cancer Res, 64, 1079, 10.1158/0008-5472.CAN-03-0799 Rocchi, 2005, p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells, Oncol Rep, 13, 1139 Trus, 2005, The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells, Leukemia, 19, 1161, 10.1038/sj.leu.2403773 Gartel, 2005, Lost in transcription: p21 repression, mechanisms, and consequences, Cancer Res, 65, 3980, 10.1158/0008-5472.CAN-04-3995 Mukherjee, 2005, c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells, J Biol Chem, 280, 17617, 10.1074/jbc.M502278200 Mitchell, 1999, Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells, Cell Growth Differ, 10, 223 Huang, 2006, A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia, Exp Hematol, 34, 1480, 10.1016/j.exphem.2006.06.019 Sundberg, 2006, The immunomodulatory benzodiazepine Bz-423 inhibits B-cell proliferation by targeting c-Myc protein for rapid and specific degradation, Cancer Res, 66, 1775, 10.1158/0008-5472.CAN-05-3476 Gottlicher, 2001, Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells, EMBO J, 20, 6969, 10.1093/emboj/20.24.6969 Vervoorts, 2006, The ins and outs of MYC regulation by posttranslational mechanisms, J Biol Chem, 281, 34725, 10.1074/jbc.R600017200 Chen, 2006, Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells, J Pharmacol Exp Ther, 319, 533, 10.1124/jpet.106.106658 Hoti, 2006, Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy, Mol Ther, 14, 768, 10.1016/j.ymthe.2006.07.009 Li, 2005, Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC, Mol Cancer Ther, 4, 1912, 10.1158/1535-7163.MCT-05-0184 Le-Niculescu, 1999, Withdrawal of survival factors results in activation of JNK pathway in neuronal cells leading to Fas ligand induction and cell death, Mol Cell Biol, 19, 751, 10.1128/MCB.19.1.751 Bug, 2005, Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells, Cancer Res, 65, 2537, 10.1158/0008-5472.CAN-04-3011 Michaelis, 2006, Valproic acid induces extracellular signal-regulated kinase 1/2 activation and inhibits apoptosis in endothelial cells, Cell Growth Differ, 13, 446, 10.1038/sj.cdd.4401759 Kuendgen, 2005, Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia, Ann Hematol, 84, 61, 10.1007/s00277-005-0026-8 Bug, 2005, Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia, Cancer, 104, 2717, 10.1002/cncr.21589 Garcia-Manero, 2006, Phase 1/2 study of the combination of 5-aza-2’-deoxycytidine with valproic acid in patients with leukemia, Blood, 108, 3271, 10.1182/blood-2006-03-009142 Valentini, 2007, Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells, Cancer Biol Ther, 6 Friedmann, 2006, Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer, J Chemother, 18, 415, 10.1179/joc.2006.18.4.415